KRAS G12C mutations account for 12% to14% of non-squamous non-small cell lung cancer (NSCLC) cases, making them the most common KRAS mutation in NSCLC. Although sotorasib and adagrasib have received accelerated approval from the US Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA), these first-generation KRAS G12C inhibitors have demonstrated only modest efficacy. Therefore, there remains a need for more effective therapies.

Divarasib—a next-generation oral inactive-state KRAS G12C inhibitor—was engineered to exhibit greater on-target potency and selectivity compared with sotorasib or adagrasib. It previously showed greater potency and selectivity than sotorasib and adagrasib in preclinical studies, as well as durable clinical benefit and a manageable safety profile in the phase I GO42144 trial.
In the phase III Krascendo 1 trial, the data show divarasib demonstrated clinically meaningful and statistically significant improvements in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) compared with sotorasib or adagrasib
Ferdinandos Skoulidis, MD, PhD, MRCP, presented the primary results at the 2026 European Society for Medical Oncology Congress in Madrid.
The global, open-label, randomized trial compared divarasib head-to-head with either sotorasib or adagrasib in previously treated patients with advanced or metastatic KRAS G12C-mutant NSCLC. Eligible patients had received one to three prior lines of systemic therapy, including platinum-based chemotherapy and a PD-(L)1 inhibitor. Additionally, patients needed to be KRAS G12C inhibitor-naïve and have no active or untreated brain metastases.
“Based on the results of the Krascendo 1 clinical trial, divarasib represents a new standard of care for patients with previously treated KRAS G12C-mutant advanced or metastatic NSCLC.”
– Ferdinandos Skoulidis, MD, PhD, MRCP
At the data cut-off (May 19, 2026), 338 patients were randomly assigned in a 1:1 ratio to receive 400 mg of divarasib once daily (n = 167) or to the control group (n = 171). Patients in the control group received either 960 mg of sotorasib once daily (n = 156) or 600 mg of adagrasib orally twice daily (n = 15). Crossover between treatment arms was not permitted; however, Dr. Skoulidis said patients who continued to experience clinical benefit were allowed to continue treatment beyond disease progression.
The primary endpoint was PFS, assessed by Blinded Independent Central Review (BICR). Key secondary endpoints included OS, confirmed ORR by BICR, time to confirmed deterioration, and duration of response (DoR) determined by BICR.
Dr. Skoulidis said patient demographics were generally balanced between the two treatment arms. The median patient age was 66 years, around 30% of patients had a history of brain metastases, and about 20% of patients had a detected KEAP1 mutation.
The Krascendo 1 trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in PFS by BICR for divarasib compared with sotorasib or adagrasib.
“Median progression-free survival with divarasib was 9.8 months, compared with 5.7 months with sotorasib or adagrasib,” Dr. Skoulidis said. “The landmark 12-month PFS rates were 43.9% with divarasib and 24% with sotorasib or adagrasib.”
Investigator-assessed PFS was consistent with the BICR-assessed PFS (11.1 months with divarasib vs. 5.6 months with sotorasib or adagrasib). This PFS benefit was consistent across patient subgroups, including those with a history of CNS metastases (6.8 months with divarasib vs. 5.7 months with sotorasib or adagrasib) and with detected KEAP1 mutation status (4.6 months with divarasib vs. 2.8 months with sotorasib or adagrasib).
Divarasib also met the study’s secondary endpoint, achieving a median OS of 17.7 months, compared with 12 months with sotorasib or adagrasib, Dr. Skoulidis said.
“Divarasib significantly prolonged OS compared with sotorasib or adagrasib, with a hazard ratio of 0.56, corresponding to a 44% reduction in the risk of death,” he said. “The landmark 12-month OS rates were 67.1% with divarasib and 49.2% with sotorasib or adagrasib.”
The OS benefit was also generally consistent across subgroups. Additionally, divarasib induced a statistically significant 25.8% increase in ORR compared with the control group.
“Among 328 response-evaluable patients, the confirmed ORR was 58% with divarasib, compared with 32% with sotorasib or adagrasib,” Dr. Skoulidis said. “Responses with divarasib occurred rapidly and were deep and durable, with a median DoR of 11.9 months in the divarasib arm versus 6.9 months in patients treated with sotorasib or adagrasib.”
Divarasib also demonstrated a more favorable safety profile compared to sotorasib or adagrasib, with a lower incidence of grade 3 or higher treatment-related adverse events (TRAEs) among patients (24.6% vs. 34.5%), a reduced rate of serious TRAEs (7.8% vs. 15.2%), and fewer TRAEs leading to treatment discontinuation (4.8% vs. 11.7%).
“The safety profile of divarasib was consistent with the known class effects of KRAS G12C inhibitors, and no new safety signals emerged. The most common TRAEs with divarasib were gastrointestinal, including diarrhea, nausea, and vomiting,” Dr. Skoulidis said. “These occurred more frequently in patients who received divarasib compared with sotorasib or adagrasib, but these were mostly grade one (35%, 32%, and 28%, respectively), manageable with standard supportive measures, and reversible.”
“Based on the results of the Krascendo 1 clinical trial, divarasib represents a new standard of care for patients with previously treated KRAS G12C mutant advanced or metastatic NSCLC,” Dr. Skoulidis said.
Looking ahead, divarasib is being evaluated in the first-line setting in combination with pembrolizumab as part of the randomized phase III Krascendo 2 trial. It is also being assessed as monotherapy in patients with untreated brain metastases in Cohort D of Krascendo 170, as well as in the adjuvant setting in the Krascendo 3 trial.
